05/01/2023
Alchemab Therapeutics has been awarded a £1.7million grant from Innovate UK to accelerate its development of a first-in-class therapy for Huntington’s disease.
The Babraham Research Campus-based biotechnology company is working with the Medicines Discovery Catapult (MDC) on preclinical studies of its panel of antibodies as it takes them towards human studies.